NIAID Review of BAA Proposals for Development of Diagnostics for Biodefense, AMR, and Emerging Infectious Diseases

A closed meeting of the National Institute of Allergy and Infectious Diseases (NIAID) Special Emphasis Panel will be held August 24-25, 2023 to review and evaluate contract proposals for the NIAID 2023 DMID Omnibus BAA (HHS–NIH–NIAID–BAA2023–1), Research Area 004—Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases (N01).

The meeting will be closed to the public in accordance with U.S. policies as the contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

The proposals support the development of promising diagnostics technologies for detection of signatures from biothreat pathogens and pathogens causing emerging, reemerging, and AMR infectious diseases, and for pandemic preparedness.

1. Next-generation Nucleic Acid Sequencing on Portable Systems
2. Rapid Protein Detection
3. Bacterial Identification and Phenotypic Antimicrobial Resistance Characterization.

Federal Register announcement